This site demonstrates one possible use of this domain. For acquisition, partnership, or investment inquiries, please use our contact link.
Ketalux
Safety

Safety and Eligibility for Ketamine Therapy

A practical, medically responsible reference on candidacy, contraindications, and the supervision standards a responsible program should meet.

Medically reviewed by: Pending medical review(draft)Last updated: May 18, 2026Evidence: Safety overview
Watch · 5s

Safety, candidacy, and realistic expectations

A short visual primer on who may be a candidate, what supervision should look like, and what 'realistic expectations' actually means.

From this video
What should a clinician screen for?+

Cardiovascular status, current medications, substance use history, psychiatric history including psychosis or bipolar disorder, pregnancy status, prior reactions to dissociatives, and your goals and supports.

Is ketamine therapy a cure?+

No. It can produce rapid but often time-limited symptom reduction for some people, and is one part of a broader plan that typically includes therapy, medication, and lifestyle support.

Who may be a candidate

  • Adults with major depressive disorder, often treatment-resistant
  • Selected patients with PTSD, certain anxiety presentations, or specific pain syndromes
  • People able to participate in informed consent and a structured care plan
Gate 1
Indication

Adult diagnosis (e.g. treatment-resistant depression) where standard care has not provided sufficient relief.

Gate 2
Medical screen

Cardiovascular status, medication review, substance use history, pregnancy status, prior reactions.

Gate 3
Psychiatric screen

No active psychosis or untreated mania; capacity for informed consent; access to integration support.

OutcomeA qualified clinician integrates all three gates — plus your goals and history — into an individualized recommendation. There is no single checklist that approves or excludes anyone on its own.
Simplified candidacy framework. Real screening is individualized and conducted by qualified clinicians.

Contraindications and cautions

  • Uncontrolled hypertension or significant cardiovascular disease
  • Active psychotic disorders
  • Certain substance use disorders or current intoxication
  • Pregnancy or breastfeeding
  • Specific medication interactions disclosed during screening

Common short-term effects

  • Dissociation and altered perception during dosing
  • Transient increases in blood pressure and heart rate
  • Nausea, dizziness, or coordination changes
  • Emotional intensity, including unexpected memories

Less common but serious considerations

  • Cardiovascular strain in vulnerable patients
  • Urinary tract toxicity with frequent or high-dose use
  • Persistent perceptual changes in rare cases
  • Psychological dependence in unsupervised settings
Less likely
More likely →
↑ More severe
Transient dissociation
Nausea / dizziness
Elevated BP / HR
Emotional intensity
Psychological dependence
Urinary toxicity (frequent use)
Persistent perceptual changes
Illustrative risk landscape — not a clinical scoring tool.

The supervision standard

A responsible program should screen thoroughly, monitor vital signs during dosing, employ trained clinicians on-site, set realistic expectations, and integrate sessions into a broader mental health plan. Be cautious of programs that minimize any of these elements.

  1. Phase 1
    Pre-dose
    Baseline vitals, consent, setting
  2. Phase 2
    Onset
    Dose administered, monitoring begins
  3. Phase 3
    Peak
    Dissociation, BP/HR closely tracked
  4. Phase 4
    Wind-down
    Effects subside, vitals re-checked
  5. Phase 5
    Discharge
    Aftercare plan, integration scheduled
A responsible supervised session has clearly defined phases and active monitoring throughout.

Setting realistic expectations

Some patients experience rapid, meaningful change. Others see partial response, and some do not respond. Durable benefit typically requires repeated dosing, integration with psychotherapy, and ongoing care. Decisions should be made jointly with clinicians who know your full history.

Frequently asked questions

Who is generally a candidate?+

Adults with major depressive disorder — particularly treatment-resistant depression — who have tried established therapies without sufficient relief, after a full medical and psychiatric screening.

Who is not a good candidate?+

People with uncontrolled cardiovascular disease, active psychosis, certain substance use disorders, pregnancy, and some other medical conditions. Final eligibility is always a clinician's call.

What are the most common side effects?+

Transient dissociation, dizziness, nausea, elevated blood pressure and heart rate, and emotional intensity. Most resolve within hours under proper monitoring.

Is medical supervision really necessary?+

Yes. Supervision ensures vitals are monitored, adverse reactions are managed quickly, and dosing remains appropriate. Programs that skip screening or monitoring warrant skepticism.

Can ketamine be addictive?+

Ketamine has documented abuse potential and can lead to psychological dependence with unsupervised, frequent, or high-dose use. Structured clinical protocols are designed to mitigate — not eliminate — this risk.

What are realistic expectations?+

Ketamine is not a cure. Some people experience meaningful, sometimes rapid, symptom reduction; others do not respond. Durable benefit usually requires repeated sessions and broader mental health care.

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.